COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02617849
Recruitment Status : Active, not recruiting
First Posted : December 1, 2015
Last Update Posted : December 20, 2019
Information provided by (Responsible Party):
Wilson Miller, Jewish General Hospital

Brief Summary:
This is a multi-center, open-label, Phase II clinical trial evaluating pembrolizumab in combination with carboplatin/paclitaxel as a treatment in unresectable locally advanced or metastatic melanoma.

Condition or disease Intervention/treatment Phase
Metastatic Malignant Melanoma Drug: Pembrolizumab Drug: Carboplatin Drug: Paclitaxel Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 30 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Pembrolizumab With Carboplatin/Paclitaxel in Patients With Metastatic Melanoma
Actual Study Start Date : May 19, 2016
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : September 2020

Arm Intervention/treatment
Experimental: Pembrolizumab, Carboplatin, Paclitaxel
Carboplatin will be administered at AUC = 6, IV over 60 minutes every 3 weeks for up to 4 doses. Paclitaxel will be administered at 175mg/m2, IV over 3 hours every 3 weeks for up to 4 doses. Pembrolizumab will be administered at 200 mg, IV over 30 minutes every 3 weeks.
Drug: Pembrolizumab
200 mg IV every 3 weeks
Other Name: MK3475

Drug: Carboplatin
AUC=6, every 3 weeks x 4

Drug: Paclitaxel
175 mg/m2, every 3 weeks x 4

Primary Outcome Measures :
  1. Overall Response Rate as assessed by RECIST 1.1 and immune-related Response Criteria [ Time Frame: 56 months ]

Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: 56 months ]
  2. Overall Survival [ Time Frame: 56 months ]
  3. Progression Free Survival [ Time Frame: 56 months ]
  4. Melanoma-associated serological markers by multiplexed array will be generated [ Time Frame: 56 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

The subject must:

  1. Be willing and able to provide written informed consent for the trial.
  2. Be ≥ 18 years of age on day of signing informed consent.
  3. Have histologically confirmed diagnosis of unresectable Stage III or metastatic melanoma.

    • Patients may not have a diagnosis of uveal melanoma.
  4. Have measurable disease based on RECIST 1.1.
  5. Have a tumor sample (FFPE archival or newly obtained biopsy) of a metastatic site that is available for biomarker analysis.
  6. Have an ECOG of 0 or 1.
  7. Demonstrate adequate organ function as below:

    • Absolute neutrophil count (ANC) ≥1.5 x 109/L
    • Platelets ≥100 x 109/L
    • Hemoglobin ≥90 g/L (may be transfused)
    • Serum creatinine OR CrCl ≤ 1.5 X upper limit of normal (ULN) OR ≥60 mL/min for subject with creatinine levels > 1.5 X institutional ULN
    • Serum total bilirubin ≤ 1.5 X ULN OR Direct bilirubin ≤ ULN for subjects with total bilirubin levels > 1.5 ULN
    • AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN OR ≤ 5 X ULN for subjects with liver metastases
    • Albumin >2.5 mg/dL
    • International Normalized Ratio (INR) or Prothrombin Time (PT)
    • Activated Partial Thromboplastin Time (aPTT) ≤ 1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants ≤1.5 X ULN unless subject is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants
  8. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.
  9. Female subjects of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study medication. Subjects of childbearing potential are those who have not been surgically sterilized or have not been free from menses for > 1 year.
  10. Male subjects should agree to use an adequate method of contraception starting with the first dose of study therapy through 120 days after the last dose of study therapy.
  11. No known active or chronic infection with HIV, Hepatitis B, or Hepatitis C.

Exclusion Criteria:

The subject must be excluded from participating in the trial if the subject:

  1. Has had prior treatment for advanced unresectable or metastatic melanoma. Prior treatment with BRAF and MEK inhibitors is permitted in this setting. A washout of at least 5-half-lives (median terminal half-life) prior to the first dose of trial treatment must have elapsed.
  2. Has received prior therapy with an anti-CTLA4, anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
  3. Has evidence of symptomatic CNS lesions as determined by the investigator. Patients with asymptomatic lesions or previously irradiated or surgically resected are eligible.
  4. Has a known additional malignancy that is progressing or requires active treatment.
  5. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy (>10 mg daily prednisone equivalents) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Inhaled or topical steroids, and adrenal replacement doses ≤ 10 mg prednisone equivalents are permitted.
  6. Has ≥ Grade 2 peripheral neuropathy.
  7. Patients with an active autoimmune disease or a documented history of autoimmune disease or syndrome that requires systemic steroids or immunosuppressive agents. Patients with vitiligo or resolved childhood asthma/atopy is an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with hypothyroidism stable on hormone replacement will not be excluded from the study.
  8. Has an active infection requiring systemic therapy.
  9. Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the treating investigator.
  10. Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
  11. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.
  12. Has a known history of active TB (Bacillus Tuberculosis)
  13. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist®) are live attenuated vaccines, and are not allowed.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT02617849

Layout table for location information
Canada, Quebec
Jewish General Hospital
Montreal, Quebec, Canada, H3T 1E2
Hopital Notre-Dame
Montreal, Quebec, Canada
Sponsors and Collaborators
Wilson Miller
Layout table for investigator information
Principal Investigator: Wilson Miller, MD, PhD Jewish General Hospital
Principal Investigator: Rahima Jamal, MD, PhD CHUM, Hopital Notre-Dame
Layout table for additonal information
Responsible Party: Wilson Miller, Medical Oncologist, Jewish General Hospital Identifier: NCT02617849    
Other Study ID Numbers: MK-3475-269
First Posted: December 1, 2015    Key Record Dates
Last Update Posted: December 20, 2019
Last Verified: December 2019
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Nerve Tissue
Nevi and Melanomas
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological